COMBINATION TRIAL OF DLV, ZDV AND 3TC AS INITIAL OR FOLLOWUP THERAPY (PART II)

这项双盲随机试验的目的是评估 和耐受性的双重和三重组合疗法， 地拉韦啶，一种非核苷类逆转录酶抑制剂。 这些 联合用药包括DLV、齐多夫定（ZDV）和拉米夫定（3 TC）。 比较ZDV联合和不联合DLV的第I部分患者加新研究 CD 4计数为200-500/mm 3且总ZDV为0-6个月的HIV+患者 将研究经验。 出现的表型和基因型变化 也将进行评估。 本研究的中期分析显示，三联疗法 比其他两个手臂都好。 本研究将于以下日期结束： 1998年初成立了数据安全监测委员会。

The aim of this double blind, randomized trial is to evaluate the safety and tolerance of double and triple combination therapies with and without delavirdine, a non-nucleoside reverse transcriptase inhibitor. These combinations will include DLV, zidovudine (ZDV), and lamivudine (3TC). Patients from Part I comparing ZDV with and without DLV plus new study HIV+ patients with CD4 counts of 200-500/mm3 and with 0-6 months total ZDV experience will be studied. Phenotypic and genotypic changes that emerge will also be evaluated. Interim analysis of this study showed the triple combination therapy to be better than either of the other two arms. The study will be closed by the Data Safety Monitoring Board early in 1998.